Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study - Zhong, W; Wang, Q; Mao, W (Lancet Oncol, 2018)
et al.